Merus Interim Data on MCLA-145: Monotherapy and Combination with Pembrolizumab
Merus Presents Interim Data on MCLA-145
Merus revealed interim data on MCLA-145 during the 2024 ASCO Annual Meeting, showcasing advancements in treatment options.
MCLA-145 Effectiveness
Monotherapy: Demonstrated promising results in standalone use.
Combination with Pembrolizumab: Indicated potential synergistic effects.
This progress signifies a positive step towards enhancing treatment outcomes for specific conditions.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.